

REMARKS

The claims are 1-5.

The above amendment is in response to points set forth in the Official Action.

Firstly, a typographical error has been corrected in claim 1.

The amendment to claim 3 deletes various rejected terms stated to not be in compliance with the written description and enablement requirements of 35 USC 112.

All of the terminology in the present claims, and in particular, claim 3, were described in original claim 3 and are enabled by the extensive disclosure at page 22, line 14 et seq.

It is noted from the Official Action, that deletion of the terminology in issue would overcome the rejections and this has essentially been accomplished by the above amendment. However, with regard to the term "trigeminal and other neuralgia," this has been amended to "neuralgia" since this is fairly disclosed in the present specification at page 22, line 19.

With regard to the rejection of the term "including" in claim 3, such term no longer appears.


With regard to the rejection of the present claims on double patenting, over claims 1, 21, and 23 of U.S. 6,784,197, attention is directed to the fact that a Terminal Disclaimer has already been filed on April 9, 2004 in the present application with respect to Serial No. 10/204,266 which matured into U.S. 6,784,197.

No further issues remaining, allowance of this application is respectfully requested.

If the Examiner has any comments or proposals for expediting prosecution, please contact undersigned at the telephone number below.

Respectfully submitted,

Edmond DIFFERDING et al.

By: 
Matthew M. Jacob
Registration No. 25,154
Attorney for Applicants

MJ/ke
Washington, D.C. 20006-1021
Telephone (202) 721-8200
Facsimile (202) 721-8250
October 18, 2004